CA
NZ
UK
AU
IND
US
Vyome Holdings, Inc. (NASDAQ:HIND) spent the first half of 2026 adding cash while holding research spending in the low seven figures. ItsQuarterly Reportfiled on 12 August showed $7.9 million of cash, no debt, and a lead candidate that has already produced statistically significant Phase …
AEON Biopharma, Inc. (NYSEAMERICAN:AEON) has spent 18 months trading with an asterisk on its ticker. On 3 August 2026 the Irvine, California drug developer said it had regained compliance with the exchange's continued listing standards, ending a deficiency dating to February 2025.
Autonomix Medical, Inc. (NASDAQ:AMIX) has spent the summer of 2026 doing two things at once: pushing a novel medical device toward the U.S. Food and Drug Administration, and working to keep enough cash in the bank to get there.
CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) has spent 2026 rebuilding itself in public. In eight months it has replaced its chief executive, hired an entirely new senior team, abandoned the single-asset strategy it was built on, and raised more money than it had ever held at …
enVVeno Medical Corporation (NASDAQ:NVNO) is a small Irvine, California device developer attacking severe deep chronic venous insufficiency, or CVI. In a healthy leg, one-way valves inside the deep veins stop blood falling back toward the feet. When those valves are destroyed, blood pools, and …
GRI Bio, Inc. (NASDAQ:GRI) is among the smallest clinical-stage biotechs on theNasdaqCapitalMarket, yet it carries one of the more intriguing mid-stage datasets in idiopathic pulmonary fibrosis. The La Jolla, California company closed at $1.95 on 12 August 2026 - aMarket Valuenear $3.5 million across …
Imunon, Inc. (NASDAQ:IMNN) is running a 500-patient pivotal cancer trial while carrying a stockMarket ValueStockTitan listed at roughly $6.8 million in mid-August 2026. That gap came into focus on 11 August, when the New Jersey biotech reported second-quarter results and filed its quarterly report.
Nexalin Technology, Inc. (NASDAQ:NXL) has produced the clinical headlines a small neurotechnology developer wants in 2026: a 77.8% anxiety response rate from a Brazilian trial, a new U.S. patent, and an FDA pivotal study now recruiting. Its shareholders have watched the stock slide to …
Revelation Biosciences, Inc. (NASDAQ:REVB) is a San Diego clinical-stage biotechnology company with eight full-time employees, noRevenueand under four million shares outstanding. On 10 July 2026 its board adopted a stockholder rights plan, the defensive structure known as a poison pill, triggered at just 10% …
SINTX Technologies, Inc. (NASDAQ:SINT) has spent 2026 fighting on two fronts: proving its silicon nitride ceramic can win commercial orders, and proving to Nasdaq that it belongs on the exchange. On 13 August the second fight ended in its favour.
Please wait processing your request...